1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

  • April 2015
  • -
  • Infiniti Research Limited
  • -
  • 83 pages

About SLE
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
TechNavio's analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.
TechNavio's report, the Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Anthera Pharmaceuticals
• BMS
• GSK
• ImmuPharma
• Merck Serono
• UCB
Other Prominent Vendors
• Amgen
• HGS
• Immunomedics
• Johnson & Johnson
• MedImmune
• Sanofi
• Teva Pharmaceutical Industries

Market Driver
• High Prevalence of Autoimmune Disease
• For a full, detailed list, view our report

Market Challenge
• Complex Etiology
• For a full, detailed list, view our report

Market Trend
• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market overview
03.2 Product offerings
04. Market Research Methodology
04.1 Market research process
04.2 Research methodology
05. Introduction
06. Disease Overview
06.1 Etiology
06.2 Epidemiology
06.3 Risk factors
06.4 Quality of life
06.5 Symptoms
06.6 Diagnosis
06.7 Management and treatment
07. SLE Pipeline Landscape
08. Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 SLE drugs market in Americas
08.3.1 Market size and forecast
08.4 SLE drugs market in Europe
08.4.1 Market size and forecast
09. Market Assessment of Benlysta
09.1.1 Benlysta revenue forecast in US
09.1.2 Benlysta revenue forecast in 5EU
09.2 Five forces analysis
10. Market Segmentation by Type
11. Market Segmentation by Therapeutic Class
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive scenario
20.1.1 Key news
20.1.2 Mergers and acquisitions
20.2 Market share analysis 2014
20.2.1 Anthera Pharmaceuticals
20.2.2 BMS
20.2.3 GSK
20.2.4 ImmuPharma
20.2.5 Merck Serono
20.2.6 UCB
20.3 Other prominent vendors
21. Key Vendor Analysis
21.1 Anthera Pharmaceuticals
21.1.1 Key facts
21.1.2 Business overview
21.1.3 Business strategy
21.1.4 Recent developments
21.1.5 SWOT analysis
21.2 Bristol-Myers Squibb
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Key product offerings
21.2.4 Revenue by geography
21.2.5 Business strategy
21.2.6 Key information
21.2.7 SWOT analysis
21.3 GlaxoSmithKline
21.3.1 Key facts
21.3.2 Business overview
21.3.3 Business segmentation
21.3.4 Business segmentation by revenue 2012 and 2013
21.3.5 Sales by geography
21.3.6 Pipeline products
21.3.7 Business strategy
21.3.8 Key information
21.3.9 SWOT analysis
21.4 ImmuPharma
21.4.1 Key facts
21.4.2 Business overview
21.4.3 Business strategy
21.4.4 Recent developments
21.4.5 SWOT analysis
21.5 Merck Serono
21.5.1 Key facts
21.5.2 Business overview
21.5.3 Geographical segmentation by revenue 2013
21.5.4 Business strategy
21.5.5 Recent developments
21.5.6 SWOT analysis
21.6 UCB
21.6.1 Key facts
21.6.2 Business overview
21.6.3 Product segmentation by revenue 2013
21.6.4 Product segmentation by revenue 2012 and 2013
21.6.5 Geographical segmentation by revenue 2013
21.6.6 Business strategy
21.6.7 Recent developments
21.6.8 SWOT analysis
22. Other Reports in this Series


List of Exhibits:
Exhibit 1: Market research methodology
Exhibit 2: Diagnosed prevalent cases of SLE 2014 and 2019
Exhibit 3: Overview of management of SLE
Exhibit 4: Global SLE drugs market 2014-2019 ($ million)
Exhibit 5: SLE drugs market in Americas 2014-2019 ($ million)
Exhibit 6: SLE drugs market in Europe 2014-2019 ($ million)
Exhibit 7: Benlysta: Global revenue 2011-2013 ($ million)
Exhibit 8: Benlysta: Revenue forecast in US 2014-2019 ($ million)
Exhibit 9: Benlysta: Revenue forecast in 5EU 2014-2019 ($ million)
Exhibit 10: Segmentation of global SLE drugs market by type
Exhibit 11: Segmentation of global SLE drugs market by therapeutic class
Exhibit 12: Segmentation of global SLE drugs market by geography 2014
Exhibit 13: Orencia: Global revenue 2011-2013 ($ million)
Exhibit 14: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 15: Bristol-Myers Squibb: Revenue by geographical segmentation 2013
Exhibit 16: GlaxoSmithKline: Business segmentation 2013
Exhibit 17: GlaxoSmithKline: Business segmentation by revenue 2012 and 2013 (US$ billion)
Exhibit 18: GlaxoSmithKline: Sales by geography 2013
Exhibit 19: GlaxoSmithKline: Pipeline products 2013
Exhibit 20: Merck Serono: Geographical segmentation by revenue 2013
Exhibit 21: UCB: Product segmentation by revenue 2013
Exhibit 22: UCB: Product segmentation by revenue 2012 and 2013 (US$ million)
Exhibit 23: UCB: Geographical segmentation by revenue 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.